These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9573653)

  • 1. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
    Pastel DA
    Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory data which differentiate meropenem and imipenem.
    Edwards JR; Turner PJ
    Scand J Infect Dis Suppl; 1995; 96():5-10. PubMed ID: 7652504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-cilastatin in the treatment of hospital infections.
    Mao P; Enrichens F; Olivero G; Sciascia C; Benedetto G; Franchello A; Olivero S
    J Chemother; 1991 Jan; 3 Suppl 1():205-7. PubMed ID: 12041766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.
    Biglino A; Bonasso M; Gioannini P
    J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.
    Yousif T; Pooyeh S; Hannemann J; Baumann J; Tauber R; Baumann K
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):475-86. PubMed ID: 10543314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
    Hellinger WC; Brewer NS
    Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C;
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    Kuti JL; Florea NR; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological changes induced by imipenem and meropenem at sub-inhibitory concentrations in Acinetobacter baumannii.
    Bernabeu-Wittel M; García-Curiel A; Pichardo C; Pachón-Ibáñez ME; Jiménez-Mejías ME; Pachón J
    Clin Microbiol Infect; 2004 Oct; 10(10):931-4. PubMed ID: 15373891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it safe to use carbapenems in patients with a history of allergy to penicillin?
    Sodhi M; Axtell SS; Callahan J; Shekar R
    J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem.
    Lakhal K; Lortat-Jacob B; Neukirch C; Pajot O; Wolff M
    Pharmacotherapy; 2007 Sep; 27(9):1334-8. PubMed ID: 17723087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenems: a potent class of antibiotics.
    Nicolau DP
    Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo.
    Kim J; Ha JR; Oh SW; Kim HG; Lee JM; Lee DG; Lee SH; Kim JG
    Biol Pharm Bull; 2007 Mar; 30(3):575-9. PubMed ID: 17329859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.